Associations of DAPSA improvement at Week 8 with change in the total PsA-modified vdH-S scores through Week 100
At Week 8, after receiving guselkumab at Week 0 and Week 4, 211 (42.8%) patients (combined guselkumab group) achieved median DAPSA improvement (decrease ≥ 12.55), 351 (71.2%) achieved DAPSA MCID (decrease ≥ 7.25), and 86 (17.4%) achieved DAPSA LDA.Saturated models demonstrated that among guselkumab-randomized patients with radiographic assessment at Week 100, greater improvement in DAPSA score at Week 8 was significantly associated with less RP of joint damage through Week 100 (parameter estimate [β] = -0.03, Multivariate association of DAPSA endpoints at Week 8 with change in total PsA-modified vdH-S score through Week 100 in guselkumab-randomized patients (saturated models). Findings of the reduced models employing backward selection of variables were consistent with those of the saturated models (Table 